The Advanced Centre for Biochemical Engineering, University College London, Torrington Place, London, WC1E 6BT, UK.
Cell Stem Cell. 2012 Dec 7;11(6):735-9. doi: 10.1016/j.stem.2012.11.013.
During Q2-Q3 2012, the cell therapy industry benefited from a number of positive external influences including advantageous changes to future FDA regulation, but stock market activity was highly mixed. The FDA approved two more products and an appreciable number of public-company-sponsored clinical trials are progressing through phases 1-3.
2012 年第二季度至第三季度期间，细胞治疗行业受益于一些积极的外部影响，包括未来 FDA 监管的有利变化，但股票市场活动高度混合。FDA 批准了另外两种产品，相当数量的由上市公司赞助的临床试验正在进行 1-3 期。
